Literature DB >> 26553363

Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology.

Melike Ozcelik1, Mesut Seker2, Emrah Eraslan3, Sinan Koca4, Dogan Yazilitas5, Ozlem Ercelep6, Ersin Ozaslan7, Serap Kaya4, Ilhan Hacibekiroglu8, Serkan Menekse9, Asude Aksoy10, Burcu Yapar Taskoylu11, Umut Varol12, Erkan Arpaci13, Aydin Ciltas14, Berna Oksuzoglu3, Nurullah Zengin5, Mahmut Gumus2, Mehmet Aliustaoglu6.   

Abstract

Most data on prognostic factors for patients with high-grade undifferentiated pleomorphic sarcoma (HGUPS) is obtained from analyses of soft tissue sarcomas. The purpose of this study was to evaluate the clinicopathologic features and their impact on outcomes specifically in patients diagnosed with HGUPS. In this multicenter trial, we retrospectively analyzed 112 patients who were diagnosed and treated at 12 different institutions in Turkey. We collected data concerning the patients, tumor characteristics, and treatment modalities. There were 69 males (61.6 %) and 43 females (38.4 %). Median age was 56 years (19-90). The most common anatomic site of tumor origin was the upper extremity. Pleomorphic variant was the predominant histological subtype. Median tumor size was 8.2 cm (0.6-30 cm). Tumors were mainly deeply seated (57.1 %). Fifty-seven patients (50.9 %) were stage II and the remainder were stage III at the time of diagnosis. Median follow-up was 30 months (2-160). The primary site of distant metastasis was the lung (73.5 %) and the second most common site was the liver (11.7 %). The 5-year overall survival, distant metastasis-free survival, and local recurrence-free survival rates were 56.3, 53.4, and 67.2 %, respectively. Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) performance score of II (p = 0.033), deep tumor location (p = 0.000), and development of distant metastasis (p = 0.004) were negatively correlated with overall survival, and perioperative radiotherapy and negative microscopic margins were significant factors for local control rates (p = 0.000 for each). Deep tumor location (p = 0.003) was the only adverse factor related to distant metastasis-free survival. Deep tumor location, ECOG performance score of II, and development of distant metastasis carry a poor prognostic implication on overall survival. These will aid clinicians in predicting survival and treatment decision.

Entities:  

Keywords:  High-grade undifferentiated pleomorphic sarcoma; Malignant fibrous histiocytoma; Prognostic factors; Soft tissue sarcoma

Mesh:

Year:  2015        PMID: 26553363     DOI: 10.1007/s13277-015-4359-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  MALIGNANT FIBROUS XANTHOMAS.

Authors:  J E O'BRIEN; A P STOUT
Journal:  Cancer       Date:  1964-11       Impact factor: 6.860

2.  Chemotherapy of malignant fibrous histiocytoma: a Southwest Oncology Group report.

Authors:  C Leite; J W Goodwin; J G Sinkovics; L H Baker; R Benjamen
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

3.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.

Authors:  S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Malignant fibrous histiocytoma: a retrospective study of 167 cases.

Authors:  M M Kearney; E H Soule; J C Ivins
Journal:  Cancer       Date:  1980-01-01       Impact factor: 6.860

5.  Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group.

Authors:  J M Coindre; P Terrier; L Guillou; V Le Doussal; F Collin; D Ranchère; X Sastre; M O Vilain; F Bonichon; B N'Guyen Bui
Journal:  Cancer       Date:  2001-05-15       Impact factor: 6.860

6.  Malignant fibrous histiocytoma of soft tissue. A population-based epidemiologic and prognostic study of 137 patients.

Authors:  B Rööser; H Willén; P Gustafson; T A Alvegård; A Rydholm
Journal:  Cancer       Date:  1991-01-15       Impact factor: 6.860

7.  Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis.

Authors:  V Le Doussal; J M Coindre; A Leroux; K Hacene; P Terrier; N B Bui; F Bonichon; F Collin; A M Mandard; G Contesso
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

8.  Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma.

Authors:  Min Suk Kim; Wan Hyeong Cho; Won Seok Song; Soo-Yong Lee; Dae-Geun Jeon
Journal:  Anticancer Res       Date:  2007 Mar-Apr       Impact factor: 2.480

9.  Prognostic factors in 227 patients with malignant fibrous histiocytoma.

Authors:  C M Pezzi; M S Rawlings; J J Esgro; R E Pollock; M M Romsdahl
Journal:  Cancer       Date:  1992-04-15       Impact factor: 6.860

10.  Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients.

Authors:  Katja Maretty-Nielsen; Ninna Aggerholm-Pedersen; Akmal Safwat; Peter Holmberg Jørgensen; Bjarne H Hansen; Steen Baerentzen; Alma B Pedersen; Johnny Keller
Journal:  Acta Orthop       Date:  2014-04-03       Impact factor: 3.717

View more
  4 in total

1.  Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?

Authors:  Jason Klein; Alex Ghasem; Samuel Huntley; Nathan Donaldson; Martin Keisch; Sheila Conway
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

2.  Serum lactate dehydrogenase as a novel prognostic factor for patients with primary undifferentiated pleomorphic sarcomas.

Authors:  Qiaowei Lin; Zhengwang Sun; Lin Yu; Qifeng Wang; Ping Zhu; Yihan Jiang; Yangbai Sun; Wangjun Yan
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-29       Impact factor: 4.553

3.  Prediction of clinical outcome and survival in soft-tissue sarcoma using a ten-lncRNA signature.

Authors:  Rong-Quan He; Qing-Jun Wei; Rui-Xue Tang; Wen-Jie Chen; Xia Yang; Zhi-Gang Peng; Xiao-Hua Hu; Jie Ma; Gang Chen
Journal:  Oncotarget       Date:  2017-05-22

4.  Undifferentiated Pleomorphic Sarcoma: Long-Term Follow-Up from a Large Institution.

Authors:  Shiqi Chen; Wending Huang; Peng Luo; Weiluo Cai; Lingge Yang; Zhengwang Sun; Biqiang Zheng; Wangjun Yan; Chunmeng Wang
Journal:  Cancer Manag Res       Date:  2019-11-27       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.